{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Section# and Name', 'Description of Change', 'Brief Rationale', 'in the IRT system.', 'Section 9.3.7 Adverse Events', 'Added \"worsening of', 'AESI list of was updated to', 'of Special Interest', 'hypertension\" as an additional', 'align with the changes in the', 'adverse event of special', 'Risk Assessment table and the', 'interest', 'IB version 10.', 'Section 9.5.4 Ultrasound', 'Added guidance on conducting', 'Added text related to', 'ultrasound for participants with', 'requirements for ADPKD', 'ADPKD based on different', 'participants as mandated by', 'clinical scenarios in the study.', 'the DIL (dated 14 Dec 2018)', 'Section 12.7, Appendix 7:', 'Changes made to provide', 'Updated French Administrative', 'Country specific requirement', 'guidance regarding the', 'Considerations and Specifics', 'conduct of the study at French', 'Requirements based on an', 'site only.', 'updated template', 'Entire protocol', 'Minor editorial and document', 'Minor, therefore have not been', 'formatting revisions', 'summarized.', '6']['2016N298481_02', 'CONFIDENTIAL', '205270', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '10', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '13', '3.', 'INTRODUCTION', '18', '3.1.', 'Study Rationale', '18', '3.2.', 'Background', '19', '3.3.', 'Benefit/Risk Assessment', '19', '3.3.1.', 'Risk Assessment', '19', '3.3.2.', 'Benefit Assessment', '33', '3.3.3.', 'Overall Benefit:Risk Conclusion', '33', '4.', 'OBJECTIVES AND ENDPOINTS', '33', '5.', 'STUDY DESIGN', '36', '5.1.', 'Overall Design', '36', '5.2.', 'Number of Participants', '37', '5.3.', 'Participant and Study Completion', '37', '5.4.', 'Scientific Rationale for Study Design', '38', '5.5.', 'Dose Justification', '38', '6.', 'STUDY POPULATION', '39', '6.1.', 'Inclusion Criteria', '39', '6.2.', 'Exclusion Criteria', '40', '6.3.', 'Lifestyle Restrictions', '42', '6.4.', 'Screen Failures', '42', '7. TREATMENTS', '42', '7.1.', 'Treatments Administered', '42', '7.2.', 'Dose Modification', '43', '7.3.', 'Method of Treatment Assignment', '45', '7.4.', 'Blinding', '45', '7.4.1.', 'Additional Considerations to Maintain the Blind', '45', '7.5.', 'Preparation/Handling/Storage/Accountability.', '46', '7.6.', 'Treatment Compliance', '46', '7.6.1.', 'Study Treatment Extended Interruption', '46', '7.7.', 'Standard of Care', '47', '7.7.1.', 'Iron Management Criteria', '47', '7.7.2.', 'Rescue Criteria', '47', '7.8.', 'Concomitant Therapy', '48', '7.8.1.', 'Permitted Medications and Non-Drug Therapies', '49', '7.8.2.', 'Prohibited Medications and Non-Drug Therapies', '49', '7.9.', 'Treatment after the End of the Study', '50', '8.', 'DISCONTINUATION CRITERIA', '50', '8.1.', 'Discontinuation of Study Treatment', '50', '8.1.1.', 'Liver Chemistry Stopping Criteria', '50', '7']['2016N298481_0', 'CONFIDENTIAL', '205270', '8.2.', 'Withdrawal from the Study', '52', '8.3.', 'Lost to Follow Up', '53', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '53', '9.1.', 'Screening and Critical Baseline Assessments', '54', '9.2.', 'Efficacy Assessments', '55', '9.3.', 'Adverse Events', '55', '9.3.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '55', '9.3.2.', 'Method of Detecting AEs and SAEs', '56', '9.3.3.', 'Follow-up of AEs and SAEs', '56', '9.3.4.', 'Regulatory Reporting Requirements for SAEs', '56', '9.3.5.', 'Events Referred to the Clinical Events Committee (CEC)', '57', '9.3.6.', 'Other Cardiovascular (CV) Events', '57', '9.3.7.', 'Adverse Events of Special Interest', '58', '9.3.8.', 'Possible Suicidality Related Adverse Events', '58', '9.3.9.', 'Pregnancy', '59', '9.4.', 'Treatment of Overdose', '59', '9.5.', 'Safety Assessments', '59', '9.5.1.', 'Height and Weight', '59', '9.5.2.', 'Blood Pressure and Heart Rate', '59', '9.5.3.', 'Electrocardiograms', '60', '9.5.4.', 'Ultrasound', '60', '9.5.5.', 'Clinical Laboratory Assessments', '61', '9.6.', 'Patient Reported Outcomes', '62', '9.6.1.', 'Chronic Kidney Disease - Anemia Questionnaire (CKD-', 'AQ)', '63', '9.6.2.', 'Patient Global Impression of Severity (PGI-S) and Patient', 'Global Impression of Change (PGI-C)', '63', '9.6.3.', 'Health Related Quality of Life (SF-36)', '63', '9.6.4.', 'Health Status (EQ-5D-5L & EQ-VAS)', '64', '9.6.5.', 'Work Productivity and Activity Impairment (WPAI-ANS-', 'CPV)', '64', '9.7.', 'Actigraphy', '64', '9.8.', 'Pharmacokinetics', '65', '9.9.', 'Genetics', '65', '9.10.', 'Storage Biomarkers', '65', '9.11. Healthcare Resource Utilization and Economics', '65', '9.12.', 'Patient Feedback Survey', '66', '10. STATISTICAL CONSIDERATIONS AND DATA ANALYSES', '66', '10.1. Primary Hypothesis', '66', '10.2. Sample Size Determination', '67', '10.2.1.', 'Sample Size Assumptions', '67', '10.2.2.', 'Sample Size Sensitivity', '67', '10.2.3.', 'Sample Size Re-Estimation or Adjustment', '68', '10.3.', 'Data Analysis Considerations', '68', '10.3.1. Analysis Populations', '68', '10.4.', 'Key Elements of Analysis Plan', '68', '10.4.1.', 'Primary Analyses', '68', '10.4.2.', 'Secondary Analyses', '69', '10.4.2.1. Principal Secondary Efficacy Analyses', '69', '8']\n\n###\n\n", "completion": "END"}